Matinas BioPharma
MTNB
55 hedge funds and large institutions have $18M invested in Matinas BioPharma in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
10% more funds holding
Funds holding: 50 → 55 (+5)
0.01% more ownership
Funds ownership: 0.25% → 0.26% (+0.01%)
16% less capital invested
Capital invested by funds: $21.5M → $18M (-$3.49M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$279K |
| 2 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
+$194K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$109K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$77.8K |
| 5 |
Renaissance Technologies
New York
|
+$26.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$51.7K |
| 2 |
VF
Virtu Financial
New York
|
-$51.6K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$47.1K |
| 4 |
IIA
IPG Investment Advisors
San Diego,
California
|
-$45K |
| 5 |
Jane Street
New York
|
-$22.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IA
51
IFP Advisors
Tampa,
Florida
| $2K | – | – | – |
|
|
SPIA
52
Steward Partners Investment Advisory
New York
| $2K | – | – | – |
|
53
Bank of America
Charlotte,
North Carolina
| $1K | -$1.57K | -40 | -55% |
|
|
IIA
54
IPG Investment Advisors
San Diego,
California
| – | -$45K | -1,148 | Closed |
|
|
SBWIC
55
Schaper Benz & Wise Investment Counsel
Neenah,
Wisconsin
| – | -$11K | -290 | Closed |
|
|
VVP
56
Venture Visionary Partners
Sylvania,
Ohio
| – | -$3.8K | -96 | Closed |
|
|
GWMIA
57
Global Wealth Management Investment Advisory
Fort Lauderdale,
Florida
| – | -$1K | -13 | Closed |
|
MTNB Hedge Fund Activity: Q3 2022 in Review
55 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2022, worth a combined $18M — down 16% from $21.5M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new MTNB positions and 4 closed out — a net gain of 5 holders — while 9 added to existing stakes and 7 trimmed.
The largest buyer was LPL Financial, adding an estimated $279K. The largest seller was BlackRock, cutting an estimated $51.7K.
- 55 institutional investors held Matinas BioPharma (MTNB) as of Q3 2022, up from 50 in Q2 2022.
- Funds reported $18M of Matinas BioPharma stock for Q3 2022, down 16% quarter-over-quarter.
- 9 funds opened new Matinas BioPharma positions in Q3 2022 and 4 closed out, a net change of +5 holders.
- The largest Matinas BioPharma buyer in Q3 2022 was LPL Financial, an estimated $279K added.
- The largest Matinas BioPharma seller in Q3 2022 was BlackRock, an estimated $51.7K sold.
Based on aggregated 13F filings for Q3 2022.